Ovid Therapeutics Statistics
Total Valuation
OVID has a market cap or net worth of $423.67 million. The enterprise value is $271.15 million.
| Market Cap | 423.67M |
| Enterprise Value | 271.15M |
Important Dates
The last earnings date was Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OVID has 186.64 million shares outstanding. The number of shares has increased by 26.81% in one year.
| Current Share Class | 186.64M |
| Shares Outstanding | 186.64M |
| Shares Change (YoY) | +26.81% |
| Shares Change (QoQ) | +66.73% |
| Owned by Insiders (%) | 2.18% |
| Owned by Institutions (%) | 51.48% |
| Float | 152.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 59.49 |
| Forward PS | 3,315.64 |
| PB Ratio | 1.92 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 38.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.17, with a Debt / Equity ratio of 0.07.
| Current Ratio | 10.17 |
| Quick Ratio | 9.88 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.77% and return on invested capital (ROIC) is -74.21%.
| Return on Equity (ROE) | -18.77% |
| Return on Assets (ROA) | -19.66% |
| Return on Invested Capital (ROIC) | -74.21% |
| Return on Capital Employed (ROCE) | -23.03% |
| Weighted Average Cost of Capital (WACC) | 5.08% |
| Revenue Per Employee | $309,652 |
| Profits Per Employee | -$1.05M |
| Employee Count | 23 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +650.66% in the last 52 weeks. The beta is 0.18, so OVID's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +650.66% |
| 50-Day Moving Average | 2.61 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 42.12 |
| Average Volume (20 Days) | 2,440,206 |
Short Selling Information
The latest short interest is 10.63 million, so 5.70% of the outstanding shares have been sold short.
| Short Interest | 10.63M |
| Short Previous Month | 10.09M |
| Short % of Shares Out | 5.70% |
| Short % of Float | 6.97% |
| Short Ratio (days to cover) | 6.06 |
Income Statement
In the last 12 months, OVID had revenue of $7.12 million and -$24.07 million in losses. Loss per share was -$0.27.
| Revenue | 7.12M |
| Gross Profit | 7.12M |
| Operating Income | -48.34M |
| Pretax Income | -24.17M |
| Net Income | -24.07M |
| EBITDA | -48.17M |
| EBIT | -48.34M |
| Loss Per Share | -$0.27 |
Balance Sheet
The company has $155.52 million in cash and $13.07 million in debt, with a net cash position of $152.53 million or $0.82 per share.
| Cash & Cash Equivalents | 155.52M |
| Total Debt | 13.07M |
| Net Cash | 152.53M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 198.27M |
| Book Value Per Share | 1.19 |
| Working Capital | 144.40M |
Cash Flow
| Operating Cash Flow | -41.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 167,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -41.95M |
| FCF Per Share | -$0.22 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -678.67% |
| Pretax Margin | -339.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OVID does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.81% |
| Shareholder Yield | n/a |
| Earnings Yield | -5.68% |
| FCF Yield | -9.90% |
Analyst Forecast
The average price target for OVID is $5.47, which is 140.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.47 |
| Price Target Difference | 140.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -71.70% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OVID has an Altman Z-Score of 0.41 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.41 |
| Piotroski F-Score | 2 |